Note: Descriptions are shown in the official language in which they were submitted.
CA 02791926 2013-10-01
Conjugation Process
DESCRIPTION
The present invention relates to a process for conjugation. In particular, it
relates to the
conjugation of saccharides and proteins using reductive amination.
BACKGROUND
Bacterial capsular polysaccharides have been widely used in immunology for
many years for
the prevention of bacterial disease. A problem with such a use, however, is
the T-
independent nature of the immune response. These antigens are thus poorly
immunogenic
in young children. This problem has been overcome through conjugating the
polysaccharide
antigens to a carrier protein (a source of T-helper epitopes) which may then
be used to elicit
a T-dependent immune response, even in the first year of life.
Various conjugation techniques are known in the art. Conjugates can be
prepared by direct
reductive amination methods as described in, US200710184072 (Hausdorff) US
4365170
(Jennings) and US 4673574 (Anderson). Other methods are described in EP-0-161-
188,
EP-208375 and EP-0-477508. The conjugation method may alternatively rely on
activation
of hydroxyl groups of the saccharide with 1-cyano-4-dimethylamino pyridinium
tetrafluoroborate (CDAP) to form a cyanate ester. Such conjugates are
described in PCT
published application WO 93/15760 Uniformed Services University and WO
95/08348 and
WO 96/29094. See also Chu C. et al Infect. Immunity, 1983 245 256.
Reductive amination involves two steps, (1) oxidation of the antigen, (2)
reduction of the
antigen and a carrier protein to form a conjugate. The oxidation step may
involve reaction
with periodate, however oxidation by periodate may lead to size reduction
(W094/05325).
SUMMARY OF INVENTION
The inventors have surprisingly found that using lower concentrations of
periodate in the
presence of low phosphate may lead to retention of size and/or the retention
of epitopes.
In a first aspect of the invention there is provided a process for conjugating
a bacterial
saccharide(s) comprising the steps of
1
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
a) reacting the bacterial saccharide with 0.001-0.7, 0.005-0.5, 0.01-0.5,
0.1-
1.2, 0.1-0.5, 0.1-0.2, 0.5-0.8, 0.1-0.8, 0.3-1.0 or 0.4-0.9 molar equivalents
of periodate to form an activated bacterial saccharide;
b) mixing the activated bacterial saccharide with a carrier protein;
c) reacting the activated bacterial saccharide and the carrier protein with a
reducing agent to form a conjugate;
or
a) reacting the bacterial saccharide with 0.001-0.7, 0.005-0.5, 0.01-0.5, 0.1-
1.2, 0.1-0.5, 0.1-0.2, 0.5-0.8, 0.1-0.8, 0.3-1.0 or 0.4-0.9 molar equivalents
of periodate to form an activated bacterial saccharide;
b) mixing the activated bacterial saccharide with a linker;
c') reacting the activated bacterial saccharide with the linker using a
reducing
agent to form a bacterial saccharide-linker;
d) reacting the bacterial saccharide-linker with a carrier protein to form a
conjugate;
wherein step a) occurs in a buffer which does not contain an amine group, and
the buffer
has a concentration between 1-100mM.
In a second aspect of the invention there is provided a conjugate obtainable
by the process
of the invention.
In a third aspect of the invention there is provided a conjugate obtained by
the process of the
invention.
In a fourth aspect of the invention there is provided an immunogenic
composition comprising
the conjugate of the invention and a pharmaceutically acceptable excipient.
In a fifth aspect of the invention there is provided a vaccine comprising the
immunogenic
composition of the invention.
In a sixth aspect of the invention there is provided a use of the immunogenic
composition of
the invention or the vaccine of the invention in the prevention or treatment
of bacterial
disease
In a seventh aspect of the invention there is provided a use of the
immunogenic composition
of the invention or the vaccine of the invention in the preparation of a
medicament for the
prevention or treatment of bacterial disease.
2
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
In a eighth aspect of the invention there is provided a method of preventing
or treating
bacterial infection comprising administration of the immunogenic composition
of the
invention or the vaccine of the invention to a patient.
In an ninth aspect of the invention there is provided an activated bacterial
saccharide,
wherein the activated bacterial saccharide comprises a repeat unit of formula
(I):
_
C H2 OH
0 (I)
" _____________ Si 0 0 S2 __ "
? ¨
_
S3 OP(02)0
HC¨CH2OH
\
CH2OH
wherein the activated bacterial saccharide comprises n repeat units and n is
between 2 and
2400, between 500 and 2000, between 750 and 1500, between 1000 and 2000 or
between
1500 and 2300.
wherein at least 0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 5%, 10% or 30% but less
than
0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 5%, 10%, 30% or 50% of Si is CH2OH
-1 --- 0 ----
I
0
CH2OH
and the remainder is 0
--- OH ----
OH
3
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
OH 0
wherein S2 is either --- 0----
_______________________________________________________________________________
__ 0_
or
0
0 CH3
CH3
and wherein S3 is either HO --- or HO
0 0
CH3 CH3
DESCRIPTION OF FIGURES
Figure 1. Size of 23F and 6B polysaccharides following periodate treatment.
The line
marked with triangles shows the size of 6B in 10mM phosphate buffer, the line
marked with
diamonds shows the size of 23F in 10mM phosphate buffer and the line marked
with
squares shows the size of 23F in 100mM phosphate buffer.
Figure 2. Comparison of immunogenicity of 23F conjugates using either CDAP or
reductive
amination conjugation. Graph a) describes the results of an ELISA assay. Graph
b)
describes the results of an opsonophagocytosis assay.
Figure 3 Evaluation of the immunogenicity of PSO6B-CRM conjugated using the
conjugation
methods described in example 4 in a Balb/c mouse model.
Figure 4 Evaluation of the immunogenicity of PSO6B-CRM conjugated using the
conjugation
methods described in example 4 in a guinea pig model.
DETAILED DESCRIPTION OF THE INVENTION
The invention relates to an improved process for conjugating an antigen to a
carrier protein.
In particular, the invention provides a process for conjugating a bacterial
saccharide(s)
comprising the steps of
4
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
a) reacting the bacterial saccharide with 0.001-0.7, 0.005-0.5, 0.01-0.5, 0.1-
1.2, 0.1-0.5, 0.1-0.2, 0.5-0.8, 0.1-0.8, 0.3-1.0 or 0.4-0.9 molar equivalents
of periodate to form an activated bacterial saccharide;
b) mixing the activated bacterial saccharide with a carrier protein;
c) reacting the activated bacterial saccharide and the carrier protein with a
reducing agent to form a conjugate;
or
a) reacting the bacterial saccharide with 0.001-0.7, 0.005-0.5, 0.01-0.5, 0.1-
1.2, 0.1-0.5, 0.1-0.2, 0.5-0.8, 0.1-0.8, 0.3-1.0 or 0.4-0.9 molar equivalents
of periodate to form an activated bacterial saccharide;
b) mixing the activated bacterial saccharide with a linker;
c') reacting the activated bacterial saccharide with the linker using a
reducing
agent to form a bacterial saccharide-linker;
d) reacting the bacterial saccharide-linker with a carrier protein to form a
1 5 conjugate;
wherein step a) occurs in a buffer which does not contain an amine group, and
the buffer
has a concentration between 1-100mM.
The term `periodate' includes both periodate and periodic acid. This term also
includes both
metaperiodate (104-) and orthoperiodate (1065-), however in one particular
embodiment the
periodate used in the method of the invention is metaperiodate. The term
`periodate' also
includes the various salts of periodate including sodium periodate and
potassium periodate.
In one embodiment the periodate used is sodium metaperiodate. When an antigen
reacts
with periodate, periodate oxidises vicinal hydroxyl groups to form carbonyl or
aldehyde
groups and causes cleavage of a C-C bond. For this reason the term 'reacting
an antigen
with periodate' includes oxidation of vicinal hydroxyl groups by periodate.
For the purposes of the invention an 'activated bacterial saccharide' is a
bacterial saccharide
which has been activated by step a) of the process of the invention.
For the purposes of the invention the term 'conjugate' indicates a bacterial
saccharide linked
covalently to a carrier protein. In one embodiment a bacterial saccharide is
linked directly to
a carrier protein. In a second embodiment a bacterial saccharide is linked to
a protein
through a spacer/linker.
The buffer used in step a) is a buffer which does not contain an amine group.
In one
embodiment the buffer is selected from the list consisting of phosphate
buffer, borate buffer,
5
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
acetate buffer, carbonate buffer, maleate buffer and citrate buffer. In a
second embodiment
the buffer is an inorganic buffer. The term inorganic buffer includes any
buffer solution
wherein the buffering capacity is due to the presence of a compound which does
not contain
carbon. Inorganic buffers of the invention include phosphate buffer and borate
buffer. In one
embodiment the buffer is phosphate buffer.
In one embodiment the buffer has a concentration between 1-100mM, 5-80mM, 1-
50mM, 1-
25mM, 10-40mM, 1-10mM, 5-15mM, 8-12mM, 10-20mM, 5-20mM, 10-50mM, around 10mM
or around 20mM. In a further embodiment the pH in step a) is pH 2.5-8.0, pH5.0-
7.0, pH 5.5-
6.5, pH 5.8-6.3, or around pH 6Ø
The term "saccharide" throughout this specification may indicate
polysaccharide, techoic
acid or oligosaccharide and includes all three. It may indicate
lipopolysaccharide (LPS) or
lipooliogosaccharide (LOS). Before use Polysaccharides may be isolated from a
source
strain or isolated from the source strain and sized to some degree by known
methods (see
for example EP497524 and EP497525; Shousun Chen Szu et al. - Carbohydrate
Research
Vol 152 p7-20 (1986)) for instance by microfluidisation. Oligosaccharides have
a low number
of repeat units (typically 5-30 repeat units) and are typically hydrolysed
polysaccharides.
In one embodiment the bacterial saccharide is a bacterial capsular saccharide.
In one
embodiment of the present invention the bacterial saccharide originates from
Group B
Streptococcus, Vibrio cholera, Streptococus pneumoniae (S.pneumoniae),
Haemophilus
influenzae (H. influenzae), Neisseria meningitidis (N. meningitidis),
Staphylococcus aureus
(S.aureus), enterococci, Salmonella Vi, or Staphylococcus epidermidis
(S.epidermidis). In a
further embodiment the bacterial saccharide originates from S.pneumoniae,
H.influenzae,
N.meningitidis, S.aureus, enterococci, Salmonella Vi, or S.epidermidis. In a
yet further
embodiment the bacterial saccharide is a bacterial capsular saccharide
selected from a list
consisting of: N. meningitidis serogroup A (MenA), B (MenB), C (MenC), W135
(MenW) or Y
(MenY), Group B Streptococcus group la, lb, II, Ill, IV, V, VI, or VII,
Staphylococcus aureus
type 5, Staphylococcus aureus type 8, Salmonella typhi (Vi saccharide), Vibrio
cholerae, or
H. influenzae type b. In one embodiment the bacterial saccharide is a capsular
saccharide
from Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V,
10A, 11A,
12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F or 33F. In a further embodiment
the
bacterial saccharide is an S.pneumoniae capsular saccharide selected from the
group
consisting of 5, 6B, 6A, 7F, 9V, 14, or 23F. Optionally the bacterial
saccharide of the
invention is an S.pneumoniae capsular saccharide 23F, 6B or 6A. In one
embodiment the
6
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
bacterial saccharide is an S.pneumoniae capsular saccharide 23F. In one
embodiment the
bacterial saccharide is an S.pneumoniae capsular saccharide 6B. In one
embodiment the
bacterial saccharide is an S.pneumoniae capsular saccharide 6A. In a yet
further
embodiment the bacterial saccharide is Haemophilus influenzae b (Hib)
polysaccharide or
oligosaccharide. In one embodiment the bacterial saccharide contains vicinal
anti diols.
The bacterial saccharide may be either a native polysaccharide or may have
been reduced
in size by a factor of no more than x2, x4, x6, x8, x10 or x20 (for instance
by microfluidization
[e.g. by Emulsiflex 0-50 apparatus] or other known technique [for instance
heat, chemical,
oxidation, son ication methods]). In one embodiment the bacterial saccharide
is
microfluidised before step a). Oligosaccharides may have been reduced in size
substantially
further [for instance by known heat, chemical, or oxidation methods].
For the purposes of the invention, "native polysaccharide" refers to a
bacterial saccharide
that has not been subjected to a process, the purpose of which is to reduce
the size of the
saccharide. A polysaccharide can become slightly reduced in size during normal
purification
procedures. Such a saccharide is still native. Only if the polysaccharide has
been subjected
to techniques which reduce a saccharide in size would the polysaccharide not
be considered
native.
The weight-average molecular weight of a bacterial saccharide suitable for
conjugation by
the process of the invention may be between 20kDa and 2000kDa, between 30kDa
and
1000kDa, between 40kDa and 500kDa, between 50kDa and 400kDa, between 75kDa and
300kDa or between 1000kDa and 2000kDa. In the case of the native 23F capsular
saccharide from S.pneumoniae, the average molecular weight of the native
polysaccharide
is between 750-1500 kDa or 1200-1300kDa. In the case of the native Hib
saccharide, the
average molecular weight of the native polysaccharide is between 100 and
250kDa. The
molecular weight or average molecular weight of a saccharide herein refers to
the weight-
average molecular weight (Mw) of the bacterial saccharide measured prior to
conjugation
and is measured by MALLS. The MALLS technique is well known in the art. For
MALLS
analysis of saccharides, two columns (TSKG6000 and 5000PWx1) may be used in
combination and the saccharides are eluted in water. Saccharides are detected
using a light
scattering detector (for instance Wyatt Dawn DSP equipped with a 10mW argon
laser at
488nm) and an inferometric refractometer (for instance Wyatt Otilab DSP
equipped with a
P100 cell and a red filter at 498nm). MALLS analyses may be carried out using
a
TSKGMPwxland 50 mM Na/K PO4, 200 mM NaCI pH 7.0 as elution buffer with 0.75
ml/min
using RI/DAWN-EOS detector. In an embodiment, the polydispersity of the
saccharide is 1-
7
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
1.5, 1-1.3, 1-1.2, 1-1.1 or 1-1.05 and after conjugation to a carrier protein,
the polydispersity
of the conjugate is 1.0-2.5, 1.0-2Ø 1.0-1.5, 1.0-1.2, 1.5-2.5, 1.7-2.2 or
1.5-2Ø All
polydispersity measurements are generated by MALLS.
Treatment with periodate may lead to a reduction in the size of the bacterial
saccharide
(sizing effect). In one embodiment the process of the invention reduces this
sizing effect.
This is seen for the 23F bacterial saccharide from Streptococcus pneumoniae
(as in
example 1). For this reason, in one embodiment the average molecular weight of
a bacterial
saccharide of the invention is between 1-1100kDa, 100-470kDa, 200-300kDa, 600-
1100kDa
or 800-1000kDa after step a) (measured by MALLS as described above). In one
embodiment the average molecular weight of the 23F saccharide is between 100-
470kDa or
200-300kDa after step a). In one embodiment the average molecular weight of
the Hib
bacterial saccharide is between 1 and 50kDa or between 5 and 10kDa after step
a).
The term "carrier protein" is intended to cover both small peptides and large
polypeptides
(>10 kDa). The carrier protein may be any peptide or protein. It may comprise
one or more
T-helper epitopes. The carrier protein may be tetanus toxoid (TT), tetanus
toxoid fragment C,
non-toxic mutants of tetanus toxin [note all such variants of TT are
considered to be the
same type of carrier protein for the purposes of this invention], polypeptides
comprising
tetanus toxin T-cell epitopes such as N19 (W02006/067632), diphtheria toxoid
(DT),
CRM197, other non-toxic mutants of diphtheria toxin [such as CRM176, CRM 197,
CRM228,
CRM 45 (Uchida et al J. Biol. Chem. 218; 3838-3844, 1973); CRM 9, CRM 45,
CRM102,
CRM 103 and CRM107 and other mutations described by Nicholls and Youle in
Genetically
Engineered Toxins, Ed: Frankel, Maecel Dekker Inc, 1992; deletion or mutation
of Glu-148
to Asp, Gln or Ser and/or Ala 158 to Gly and other mutations disclosed in US
4709017 or
US 4950740; mutation of at least one or more residues Lys 516, Lys 526, Phe
530 and/or
Lys 534 and other mutations disclosed in US 5917017 or US 6455673; or fragment
disclosed in US 5843711] (note all such variants of DT are considered to be
the same type
of carrier protein for the purposes of this invention), pneumococcal
pneumolysin (Kuo et al
(1995) Infect lmmun 63; 2706-13), OMPC (meningococcal outer membrane protein ¨
usually
extracted from N. meningitidis serogroup B ¨ EP0372501), synthetic peptides
(EP0378881,
EP0427347), heat shock proteins (WO 93/17712, WO 94/03208), pertussis proteins
(WO
98/58668, EP0471177), cytokines, lymphokines, growth factors or hormones (WO
91/01146), artificial proteins comprising multiple human CD4+ T cell epitopes
from various
pathogen derived antigens (Falugi et al (2001) Eur J Immunol 31; 3816-3824)
such as N19
protein (Baraldoi et al (2004) Infect lmmun 72; 4884-7) pneumococcal surface
protein PspA
(WO 02/091998), iron uptake proteins (WO 01/72337), toxin A or B of C.
difficile (WO
8
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
00/61761), H. influenzae Protein D (EP594610 and WO 00/56360), pneumococcal
PhtA
(WO 98/18930, also referred to Sp36), pneumococcal PhtD (disclosed in WO
00/37105, and
is also referred to Sp036D), pneumococcal PhtB (disclosed in WO 00/37105, and
is also
referred to Sp036B), or PhtE (disclosed in W000/30299 and is referred to as
BVH-3).
In one embodiment of the invention the carrier protein is selected from the
group consisting
of: tetanus toxoid (TT), fragment C of tetanus toxoid, diphtheria toxoid (DT),
CRM197,
Pneumolysin (Ply), protein D, PhtD, PhtDE and N19. In a further embodiment the
carrier
protein is CRM197. In a still further embodiment the carrier protein is
tetanus toxoid (TT).
In one embodiment step a) is carried out in the dark.
When an antigen reacts with periodate, periodate oxidises vicinal hydroxyl
groups to form
carbonyl or aldehyde groups and causes cleavage of a C-C bond. The oxidation
step (step
a)) may occur as described below:
CH20H CH2OH
0
________________________ ? Nal04
)1x. __
________________________________________________________ 0
?
OH OH 0 0
When low concentrations of buffer, in particular phosphate buffer and low
amounts of
periodate are used, this may reduce the sizing effect described above.
Streptococcus pneumoniae capsular saccharides contain vicinal hydroxyl groups
which are
capable of being oxidised by periodate as can be seen from the structures of
the repeated
regions shown below:
PSI
9
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
CH3
11H) _____ 0
\I , ________ COON
u 0 COON
NHAc /OH
\ OH 0
0
OH
0¨
OH
PS4
OH OH
OH N c
OH OH
0 ) NHAc OH 0
\ OH OH
/
0) ________________________ 0 NHAc
CH3
\CI>)111COOH
CH V
3 0
PS5
CH3COOH
6N 0
OH c OH
s 0
CH2OH OH NHAc
C)I-1 /
)
r
) ___________________________ \ __ 0
40 0_
,0
3
0 0
OH CH3 NHAc
CA 02791926 2012-09-04
WO 2011/110531 PCT/EP2011/053400
PS 6A
0
I I
¨]., *
/
I _
OH H 0
HO
0
OH
HO 0 _______
HO
0
*
HO OH
OH
0
PS 6B
HO al 6.
..1
0.,,:,
a '1.,==F2 -
.....4%)."'
R.ha
1
.::
H 0
OH
a
'..
QH Rib
PS9
11
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
CH2OH
0
COON
010[CH2OH OH(A
__________ 0 c)
OH(Ac)\
__________ / CH OH
C1)1-2 0 CH OH OH OH __ 0¨
OH C)¨q ___________________ om) :f
N c OH
OH (Ac)
OH
1 ______________________________
PS7F
OH OH
CH OH )-0
OH 0¨
011 ____________________ 2 0(:)1¨ ())
OH 0 __ 0 __ C-f2 NHAc
CH3 CH20H OH H
0
C ::)1-1
H OH
OH 0 0 r
OH
OH CH3
NHAc
OH
PS14
12
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
CH OH
0
0 FOH2
CH OH
2
CH20
0 OH
OH _____________________________
CH2OH
0
OH
0
NHAc
OH ______
PS19F
OH OH
0
ofL()_OH
CH20 H OH OP(02)0¨
0
OH N c OH __________ 0
CH3
PS19A
CH20H
0
OH OH
OP(0 )0-
CH20H 0 2
OH N c =
\\L¨
*H
3
PS23F
13
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
CH2OH CH2OH
0
OH 0
0 ___________________________________________ 0-
OH 0 CH3
AH OP(02)0
)0H O CH-CH2OH
_______________________ 0
CH2OH
CH3
PS18C
CH2OH
0
CH2OH CH OH 0 OH 0_010-0-
OH
cH3
OH CH2OH OP (02)0¨CH2CHOHCH2OH
______________________ 0
OH ________________________ 0
OH
In one embodiment less than 0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 5%, 10%, 30% or
50%
of the vicinal diols of the bacterial saccharide become oxidised during step
a).
In one embodiment the carbonyl group produced in step a) reacts with an amine
group on
the carrier protein in step c). This may occur according to the following
reaction scheme:
NaBH pN
PS-CH + H p- Carrier -OH_N H _Carrier
I I protein 2 protein
0
In one embodiment the bacterial saccharide is present at a concentration of
between 0.2g/I
and 14g/I 8g/I and 12g/I, 10 g/I and 12g/I, 1g/I and 4g/I, 0.2g/I and 1g/I or
between 0.4g/I and
14
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
0.6g/1 or around 11g/I or around 0.5g/I in step a). In one embodiment the
initial concentration
of carrier protein in step b) is between 0.5g11 and 35g11, 25g/1 and 35g11,
0.5g/1 and 5g/1 or
between 0.8g/1 and 2g11 or around 32g/1 or 1g/I. In a further embodiment the
initial
concentration of activated bacterial saccharide in step b) is between 0.2g11
and 20g11, 10g/I
and 28g11, or 0.2g/I and 4g/1 or between 1g/I and 2g/1 or around 15g11 or 1.6
g/I. In a further
embodiment the initial ratio of activated bacterial saccharide to carrier
protein in step b) is
2.0:1 to 0.1:1, 1.8:1 to 0.4:1, 1.4:1 to 1.6:1, 1:1 to 1.4:1, 1.8:1 to 1.6:1,
0.8:1 to 0.4:1, 0.7:1
to 0.5:1, or 0.7:1 to 0.6:1(w/w). In a further embodiment the final ratio of
carrier protein to
bacterial saccharide after step c) or c') is 0.5:1 to 4:1, 0.8:1 to 3.2:1,
0.5:1 to 1.8:1, 1.4:1 to
1.8:1, 1:1 to 1.2:1 or 2.5:1 to 3.5:1.
In one embodiment the temperature of the reaction in step a) is 4-40 C, 10-32
C, 17-30 C or
22-27 C. Typically this temperature is maintained through step a). The
reaction temperature
during step c) is 4-40 C, 10-32 C, 17-30 C or 22-27 C. Typically this
temperature is
maintained through step c).
In one embodiment step a) of the process of the invention takes place in less
than 30 hours,
between Sand 25 hours, between 15 and 25 hours, between 30 minutes and 25
hours,
between 1 hour and 35 hours, between 10 and 20 hours, or between 15 and 20
hours
around 18 hours or around 1 hour. In one embodiment step c) of the process of
the
invention takes place in between 10-60 hours, 10-20 hours, 20-60 hours,
between 30-50
hours, or between 35-45 hours.
Conjugation may also occur through the addition of a hetero-or homo-
bifunctional linker
using the chemistry of the invention. One end of the linker will react with
the activated
antigen by reductive amination, however the other end of the linker may react
with the carrier
protein using any type of chemistry. For this reason the linker will contain
at least one
reactive amino group, if the linker is homo-bifunctional it will contain two
reactive amino
groups, if the linker is hetero-bifunctional it will contain one reactive
amino group and a
different reactive group, in one embodiment this second reactive group is a
reactive carbonyl
group. In one embodiment the linker is between 1 and 20 Angstroms in length.
In a further
embodiment the linker has between 4 and 20, 4 and 12, or Sand 10 carbon atoms.
A
possible linker is adipic acid dihydrazide (ADH). Other linkers include B-
propionamido (WO
00/10599), nitrophenyl-ethylamine (Geyer et al (1979) Med. Microbiol. lmmunol.
165; 171-
288), haloalkyl halides (US4057685), glycosidic linkages (US4673574,
US4808700), hexane
diamine and 6-aminocaproic acid (US4459286).
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
In general the following types of chemical groups on the carrier protein can
be used for
coupling / conjugation as the second reactive group:
A) Carboxyl (for instance via aspartic acid or glutamic acid). In one
embodiment this group is
linked to an amino group on a linker with carbodiimide chemistry e.g. with
EDAC (1-Ethy1-3-
(3-dimethylaminopropyl)carbodiimide)).
Note: instead of EDAC above, any suitable carbodiimide may be used.
B) Amino group (for instance via lysine). In one embodiment this group is
linked to a
carboxyl group on a linker with carbodiimide chemistry e.g. with EDAC. In
another
embodiment this group is linked to hydroxyl groups activated with CDAP or CNBr
on a linker;
to linkers having an aldehyde group; to linkers having a succinimide ester
group.
C) Sulphydryl (for instance via cysteine). In one embodiment this group is
linked to a bromo
or chloro acetylated linker with maleimide chemistry. In one embodiment this
group is
activated/modified with bis diazobenzidine.
D) The protein could be modified to contain an alkynyl or azide group , this
could be
conjugated to the linker using the 'click' chemistry (described in Tetrahedron
letters (June
2005) 46:4479-4482).
Note: instead of EDAC above, any suitable carbodiimide may be used.
Reducing agents which are suitable for use in the process of the invention
include the
cyanoborohydrides, such as sodium cyanoborohydride, borane-pyridine, or
borohydride
exchange resin. In one embodiment the reducing agent is sodium
cyanoborohydride. In one
embodiment between 0.5 and 2, 0.6 and 1.5 or 0.8 and 1.2 or around 1.0 molar
equivalent of
sodium cyanoborohydride is used in step c). In a further embodiment the
reducing agent
comprises sodium triacetoxyborohydride, in a further embodiment between 2 and
10 or
between 3 and 9 molar equivalent or around 2.5 molar equivalent of sodium
triacetoxyborohydride is used in step c).
Before step c) the activated bacterial saccharide and the carrier protein may
be lyophilised.
In one embodiment the activated bacterial saccharide and the carrier protein
are lyophilised
together. This can occur before step b), or after step b). In one embodiment
the lyophilisation
takes place in the presence of a non-reducing sugar, possible non-reducing
sugars include
sucrose, trehalose, raffinose, stachyose, melezitose, dextran, mannitol,
lactitol and palatinit.
16
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
In a further embodiment the non-reducing sugar is selected from the group
consisting of
sucrose, treha lose or man nitol.
In one embodiment steps b) and/or c) are carried out in DMSO
(dimethylsulfoxide) solvent.
In a further embodiment steps b) and/or c) are carried out in DMF
(dimethylformamide)
solvent. The DMSO or DMF solvent may be used to reconstitute the activated
bacterial
saccharide and carrier protein which has been lyophilised.
At the end of step c) there may be unreacted carbonyl groups remaining in the
conjugates,
these may be capped using a suitable capping agent. In one embodiment this
capping agent
is sodium borohydride (Na131-14), for example the product of step c) may be
reacted with
sodium borohydride for for 15 mins-15hrs, 15mins-45mins, 2-10hrs or 3-5hrs,
around 30
mins or around 4 hrs. In a further embodiment capping is achieved by mixing
the product of
step c) with around 2 molar equivalents or between 1.5 and 10 molar
equivalents of NaBH4.
The invention also provides a further step e) of purifying the conjugate, step
e) may
comprise diafilitration, for example diafiltration with a cut-off of 100kDa.
In addition or
alternatively step e) may comprise ion exchange chromatography. In a further
embodiment
step e) may comprise size exclusion chromatography. In one embodiment the
process of
claims 1-51 comprises a further step f), wherein the conjugate is sterile
filtered.
The conjugate may also be mixed with further antigens. In one embodiment the
further
antigens comprise at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or
20 S.pneumoniae
saccharides selected from the group consisting of 1,2, 3,4, 5, 6A, 6B, 7F, 8,
9N, 9V, 10A,
11A, 12F, 14, 15B, 17F, 180, 19A, 19F, 20, 22F, 23F and 33F. In one embodiment
the
further antigens comprise S.pneumoniae saccharides 4, 6B, 9V, 14, 180, 19F and
23F. In
one embodiment the further antigens comprise S.pneumoniae saccharides 4, 6B,
9V, 14,
180 and 19F. In one embodiment the further antigens comprise S.pneumoniae
saccharides
4, 9V, 14, 180, 19F and 23F.In one embodiment the further antigens comprise
S.pneumoniae saccharides1, 4, 5, 6B, 7F, 9V, 14, 180, 19F and 23F. In one
embodiment
the further antigens comprise S.pneumoniae saccharides1, 4,5, 6B, 7F, 9V, 14,
180, and
19F. In one embodiment the further antigens comprise S.pneumoniae
saccharides1, 4, 5,
7F, 9V, 14, 180, 19F and 23F. In one embodiment the further antigens comprise
S.pneumoniae saccharides1, 3,4, 5, 6A, 6B, 7F, 9V, 14, 180, 19A, 19F and 23F.
In one
embodiment the further antigens comprise S.pneumoniae saccharides1, 3, 4, 5,
6A, 6B, 7F,
9V, 14, 180, 19A and 19F. In one embodiment the further antigens comprise
S.pneumoniae
saccharides1, 3,4, 5, 6A, 7F, 9V, 14, 180, 19A, 19F and 23F. In one embodiment
the
17
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
further antigens comprise S.pneumoniae saccharidesl, 4, 5, 6A, 6B, 7F, 9V, 14,
180, 19A,
19F and 23F. In one embodiment the further antigens comprise S.pneumoniae
saccharidesl, 4,5, 6A, 6B, 7F, 9V, 14, 180, 19A and 19F. In one embodiment the
further
antigens comprise S.pneumoniae saccharidesl, 4, 5, 6A, 7F, 9V, 14, 180, 19A,
19F and
23F.
Any of the saccharides listed as 'further antigens' are optionally conjugated
to a carrier
protein either by the process of the invention or by a different process.
Optionally these
further antigens are conjugated to the carrier proteins listed above.
In an embodiment, the further antigens comprise S. pneumoniae capsular
saccharide 1
conjugated to protein D or 0RM197. In an embodiment, the further antigens
comprise S.
pneumoniae capsular saccharide 3 conjugated to protein D, 0RM197, pneumolysin
or PhtD
or fragment or fusion protein thereof. In an embodiment, the further antigens
comprise S.
pneumoniae capsular saccharide 4 conjugated to protein D or 0RM197. In an
embodiment,
the further antigens comprise S. pneumoniae capsular saccharide 5 conjugated
to protein D
or CRM197. In an embodiment, the further antigens comprise S. pneumoniae
capsular
saccharide 6B conjugated to protein D or CRM197. In an embodiment, the further
antigens
comprise S. pneumoniae capsular saccharide 7F conjugated to protein D or
0RM197. In an
embodiment, the further antigens comprise S. pneumoniae capsular saccharide 9V
conjugated to protein D or 0RM197. In an embodiment, the further antigens
comprise S.
pneumoniae capsular saccharide 14 conjugated to protein D or 0RM197. In an
embodiment,
the further antigens comprise S. pneumoniae capsular saccharide 23F conjugated
to protein
D or CRM197. In an embodiment, the further antigens comprise S. pneumoniae
capsular
saccharide 180 conjugated to tetanus toxoid or 0RM197. In an embodiment, the
further
antigens comprise S. pneumoniae capsular saccharide 19A conjugated to
pneumolysin or
0RM197. In an embodiment, the further antigens comprise S. pneumoniae capsular
saccharide 22F conjugated to 0RM197 or PhtD or fragment of fusion protein
thereof. In an
embodiment, the further antigens comprise S. pneumoniae capsular saccharide 6A
conjugated to pneumolysin or a H. influenzae protein, optionally protein D or
PhtD or fusion
protein thereof or 0RM197. In an embodiment, the further antigens comprise S.
pneumoniae
capsular saccharide 60 conjugated to pneumolysin or a H. influenzae protein,
optionally
protein D or PhtD or fusion protein thereof or CRM197. In an embodiment, the
further
antigens comprise S. pneumoniae capsular saccharide 19F conjugated to
Diphtheria toxoid
(DT).
18
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
The further antigens may also comprise Streptococcus pneumoniae proteins. In
one
embodiment the further antigens comprise at least 1 protein selected from the
group
consisting of the Poly Histidine Triad family (PhtX), Choline Binding protein
family (CbpX),
CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate
chimeric proteins
(or fusions), pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and
Sp133.
The further antigens may also comprise antigens from further bacterial
species. In one
embodiment the vaccine or immunogenic composition comprises antigens
originating from
S.pneumoniae (S. pneumoniae), Haemophilus influenzae (H. Influenzae),
Neisseria
meningitidis (N. Meningitidis),Escherichia coli ( E.col)i, Moraxella
cattharlis (M.cattarhalis),
tetanus, diphtheria, pertussis, Staphylococcus epidermidis (S.epidermidis),
enterococci,
Pseudomonas or Staphylococcus aureus (S. aureus).
In one embodiment the further antigens comprise M.cattarhalis antigens,
preferred
M.cattarhalis antigens are: OMP106 [WO 97/41731 (Antex) & WO 96/34960 (PMC)];
OMP21; LbpA & LbpB [WO 98/55606 (PMC)]; TbpA & TbpB [WO 97/13785 & WO 97/32980
(PMC)]; CopB [Helminen ME, et al. (1993) Infect. lmmun. 61:2003-2010]; UspA1/2
[WO
93/03761 (University of Texas)]; and OmpCD. Examples of non-typeable
Haemophilus
influenzae antigens which can be included in a combination vaccine (especially
for the
prevention of otitis media) include: Fimbrin protein [(US 5766608 - Ohio State
Research
Foundation)] and fusions comprising peptides therefrom [eg LB1(f) peptide
fusions; US
5843464 (OSU) or WO 99/64067]; 0MP26 [WO 97/01638 (Cortecs)]; P6 [EP 281673
(State
University of New York)]; TbpA and TbpB; Hia; Hmw1,2; Hap; and D15.
In a further embodiment the further antigens comprise Diphtheria toxoid (DT),
tetanus toxoid
(TT), and pertussis components [typically detoxified Pertussis toxoid (PT) and
filamentous
haemagglutinin (FHA) with optional pertactin (PRN) and/or agglutinin 1+2], for
example the
marketed vaccine INFANRIX-DTPaTM (SmithKlineBeecham Biologicals) which
contains DT,
TT, PT, FHA and PRN antigens, or with a whole cell pertussis component for
example as
marketed by SmithKlineBeecham Biologicals s.a., as TritanrixTM. In a further
embodiment
the further antigens comprise Hepatitis B surface antigen (HepB).
In a further embodiment the further antigens comprise the PRP capsular
saccharide of
H.influenzae (Hib).
19
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
In a further embodiment the further antigens comprise at least one capsular
saccharide from
N.meningitidis A, C, W or Y. In a further embodiment the further antigens
comprise at least
one conjugate of a capsular saccharide from N.meningitidis A, C, W or Y.
The conjugate may also be mixed with an adjuvant. Suitable adjuvants include,
but are not
limited to, aluminium salts (aluminium phosphate or aluminium hydroxide),
monophosphoryl
lipid A (for example 3D-MPL), saponins (for example Q521), oil in water
emulsions, blebs or
outer membrane vesicle preparations from Gram negative bacterial strains (such
as those
taught by W002/09746), lipid A or derivatives thereof, alkyl glucosamide
phosphates or
combinations of two or more of these adjuvants.
In a further embodiment the conjugate of the invention is mixed with a
pharmaceutically
acceptable excipient.
In a further aspect of the invention there is provided a conjugate obtainable
by the process of
the invention. In a further aspect of the invention there is provided a
conjugate obtained by
the process of the invention. The invention also provides an immunogenic
composition
comprising the conjugate of the invention and a pharmaceutically acceptable
excipient. In
one embodiment the pharmaceutical acceptable excipient does not contain a
chloride salt, in
a further embodiment the pharmaceutical excipient does not contain sodium
chloride. In one
embodiment the pharmaceutical excipient comprises a buffer selected from the
group
consisting of maleate, tris, or citrate. In a further embodiment the buffer is
maleate buffer.
The immunogenic composition of the invention may comprise further antigens, in
particular
those described as 'further antigens' above. The immunogenic composition may
comprise
an adjuvant, particularly those described above.
The invention also provides a vaccine comprising the immunogenic composition
of the
invention.
The vaccine preparations containing immunogenic compositions of the present
invention
may be used to protect or treat a mammal susceptible to infection, by means of
administering said vaccine via systemic or mucosa! route. These
administrations may
include injection via the intramuscular, intraperitoneal, intradermal or
subcutaneous routes;
or via mucosal administration to the oral/alimentary, respiratory,
genitourinary tracts.
Intranasal administration of vaccines for the treatment of pneumonia or otitis
media is
possible (as nasopharyngeal carriage of pneumococci can be more effectively
prevented,
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
thus attenuating infection at its earliest stage). Although the vaccine of the
invention may be
administered as a single dose, components thereof may also be co-administered
together at
the same time or at different times (for instance pneumococcal saccharide
conjugates could
be administered separately, at the same time or 1-2 weeks after the
administration of the
any bacterial protein component of the vaccine for optimal coordination of the
immune
responses with respect to each other). In addition to a single route of
administration, 2
different routes of administration may be used. For example, saccharides or
saccharide
conjugates may be administered IM (or ID) and bacterial proteins may be
administered IN
(or ID). In addition, the vaccines of the invention may be administered IM for
priming doses
and IN for booster doses.
The content of protein antigens in the vaccine will typically be in the range
1-100m,
optionally 5-50m, most typically in the range 5 - 25m. Following an initial
vaccination,
subjects may receive one or several booster immunizations adequately spaced.
Vaccine preparation is generally described in Vaccine Design ("The subunit and
adjuvant
approach" (eds Powell M.F. & Newman M.J.) (1995) Plenum Press New York).
Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877.
Although the vaccines of the present invention may be administered by any
route,
administration of the described vaccines into the skin (ID) forms one
embodiment of the
present invention. Human skin comprises an outer "horny" cuticle, called the
stratum
corneum, which overlays the epidermis. Underneath this epidermis is a layer
called the
dermis, which in turn overlays the subcutaneous tissue. Researchers have shown
that
injection of a vaccine into the skin, and in particular the dermis, stimulates
an immune
response, which may also be associated with a number of additional advantages.
Intradermal vaccination with the vaccines described herein forms an optional
feature of the
present invention.
The conventional technique of intradermal injection, the "mantoux procedure",
comprises
steps of cleaning the skin, and then stretching with one hand, and with the
bevel of a narrow
gauge needle (26-31 gauge) facing upwards the needle is inserted at an angle
of between
10-15 . Once the bevel of the needle is inserted, the barrel of the needle is
lowered and
further advanced whilst providing a slight pressure to elevate it under the
skin. The liquid is
then injected very slowly thereby forming a bleb or bump on the skin surface,
followed by
slow withdrawal of the needle.
21
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
More recently, devices that are specifically designed to administer liquid
agents into or
across the skin have been described, for example the devices described in WO
99/34850
and EP 1092444, also the jet injection devices described for example in WO
01/13977; US
5,480,381, US 5,599,302, US 5,334,144, US 5,993,412, US 5,649,912, US
5,569,189, US
5,704,911, US 5,383,851, US 5,893,397, US 5,466,220, US 5,339,163, US
5,312,335, US
5,503,627, US 5,064,413, US 5,520, 639, US 4,596,556, US 4,790,824, US
4,941,880, US
4,940,460, WO 97/37705 and WO 97/13537. Alternative methods of intradermal
administration of the vaccine preparations may include conventional syringes
and needles,
or devices designed for ballistic delivery of solid vaccines (WO 99/27961), or
transdermal
patches (WO 97/48440; WO 98/28037); or applied to the surface of the skin
(transdermal or
transcutaneous delivery WO 98/20734 ; WO 98/28037).
When the vaccines of the present invention are to be administered to the skin,
or more
specifically into the dermis, the vaccine is in a low liquid volume,
particularly a volume of
between about 0.05 ml and 0.2 ml.
The content of antigens in the skin or intradermal vaccines of the present
invention may be
similar to conventional doses as found in intramuscular vaccines (see above).
However, it is
a feature of skin or intradermal vaccines that the formulations may be "low
dose".
Accordingly the protein antigens in "low dose" vaccines are optionally present
in as little as
0.1 to 10[tg or 0.1 to 5 ,g per dose; and the saccharide (optionally
conjugated) antigens may
be present in the range of 0.01-1m, or between 0.01 to 0.5 ,g of saccharide
per dose.
As used herein, the term "intradermal delivery" means delivery of the vaccine
to the region of
the dermis in the skin. However, the vaccine will not necessarily be located
exclusively in
the dermis. The dermis is the layer in the skin located between about 1.0 and
about 2.0 mm
from the surface in human skin, but there is a certain amount of variation
between
individuals and in different parts of the body. In general, it can be expected
to reach the
dermis by going 1.5 mm below the surface of the skin. The dermis is located
between the
stratum corneum and the epidermis at the surface and the subcutaneous layer
below.
Depending on the mode of delivery, the vaccine may ultimately be located
solely or primarily
within the dermis, or it may ultimately be distributed within the epidermis
and the dermis.
In one aspect of the invention is provided a vaccine kit, comprising a vial
containing an
immunogenic composition of the invention, optionally in lyophilised form, and
further
22
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
comprising a vial containing an adjuvant as described herein. It is envisioned
that in this
aspect of the invention, the adjuvant will be used to reconstitute the
lyophilised immunogenic
composition.
A further aspect of the invention is a method of immunising a human host
against bacterial
disease infection comprising administering to the host an immunoprotective
dose of the
immunogenic composition or vaccine or kit of the invention. A further aspect
of the invention
is a method of immunising a human host against infection caused by S.
pneumoniae and/or
Haemophilus influenzae comprising administering to the host an
immunoprotective dose of
the immunogenic composition or vaccine or kit of the invention.
A further aspect of the invention is an immunogenic composition of the
invention for use in
the treatment or prevention of bacterial disease. A further aspect of the
invention is an
immunogenic composition of the invention for use in the treatment or
prevention of disease
caused by S.pneumoniae and/or Haemophilus influenzae infection
A further aspect of the invention is use of the immunogenic composition or
vaccine or kit of
the invention in the manufacture of a medicament for the treatment or
prevention of bacterial
diseases. A further aspect of the invention is use of the immunogenic
composition or vaccine
or kit of the invention in the manufacture of a medicament for the treatment
or prevention of
diseases caused by S. pneumoniae and/or Haemophilus influenzae infection.
The invention also provides an activated bacterial saccharide, wherein the
activated
bacterial saccharide comprises a repeat unit of formula (I):
_
C H2 OH
0 (I)
" _____________ Si 0 0 S2 __ "
? ¨
_
S3 OP(02)0
H 2C¨CH OH
\
CH2OH
23
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
wherein the activated bacterial saccharide comprises n repeat units and n is
between 2 and
2400, between 20 and 2000, between 50 and 1500, between 1000 and 2000, between
1000
and 2500 or between 1500 and 2300.
wherein at least 0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 5%, 10% or 30% but less
than
0.001%, 0.01%, 0.1%, 0.5%, 1%, 2%, 5%, 10%, 30% or 50% of Si is
CH2OH
CH20H
0
OH
and the remainder is
OH
wherein S2 is either --- OH 0 0---- or
0
CH3 0
CH3
and wherein S3 is either HO H or HO
0 0
CH3 CH3
In an embodiment less than 0.001%, 0.1%, 0.5% 1%, 2%, 3%, 5%, 10%, 30% or 50%
of S2
is
(5
0
CH3
24
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
'
In an embodiment less than 0.1%, 0.5%, 1%, 2%, 3%, 5%, 10%, 30% or 50% of S3
is
HO C13----
0
= CH3
1 0 "Around" or "approximately" are defined as within 10% more or less of
the given figure for
the purposes of the invention.
The terms "comprising", "comprise" and "comprises" herein are intended by the
inventors to
be optionally substitutable with the terms "consisting of", "consist of" and
"consists of",
respectively, in every instance.
Embodiments herein relating to "vaccine compositions" of the invention are
also applicable
to embodiments relating to "immunogenic compositions" of the invention, and
vice versa.
All references or patent applications cited within this patent specification
are incorporated by
reference herein.
In order that this invention may be better understood, the following examples
are set forth.
These examples are for purposes of illustration only, and are not to be
construed as limiting
the scope of the invention in any manner.
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
EXAMPLES
Example 1 ¨ Oxidation of 23F and 6B using periodate
Polysaccharides (PS) 23F or 6B were dissolved in 100mM KH2PO4 (pH 7.4), 10mM
KH2PO4
or WFI, to form solutions of 2mg PS/ml. The solution was incubated for 2 hours
under
agitation at room temperature. After this time the pH was adjusted to pH 6.0
with 1NHCI.
Periodate was added as a powder or in liquid form (10mg/m1 in WFI) in various
amounts to
achieve a range of molar ratios (table 1). The solutions were incubated for 17
hours at room
temperature (20-25 C), after which time the samples were dialyzed or
diafiltered against
WFI.
High performance gel filtration chromatography coupled with refractive index
and multiangle
laser lights scattering (MALLS-) detectors was used to measure the molecular
weight. Size
exclusion media (TSK5000PWXL-Tosoh) was used to profile the molecular size
distribution
of the polysaccharide (elution 0.5m1/min in NaCI 0.2M-NaN3 0.02%).
Table 1 and figure 1 describe the results of these experiments. These
demonstrate that for
the 23F saccharide substantial sizing occurs on oxidation using high molar
equivalents of
periodate in 100mM phosphate buffer. This sizing effect can be reduced by
reducing the
concentration of phosphate buffer or the molar equivalents of periodate used.
26
CA 02791926 2014-02-19
=
VB64154
Table 1:
23F 6B
molar molar
equivalent equivalent
of Size of
Size
Sample periodate Buffer
(KDa) Sample periodate buffer (KDa)
10mM
23F native 0 Water 861 6B
0 phosphate 1022
10mM 10mM
23F native 0 phosphate 847 6B
0.1 phosphate 975
100mM 10mM
23F native 0 phosphate 860 6B
0.2 phosphate 990
23FATCC 100mM 10mM
native 0 phosphate 1655 6B
0.3 phosphate 961
100mM 10mM
23F 1 phosphate <1 6B
0.75 phosphate 868
23F 1 Water 36
100mM
23F 1.2 phosphate <1
100mM
23FATCC 1 phosphate 2
100mM
23FATCC 0.125 phosphate 39
10mM
23F 0.1 phosphate 466.9
10mM
23F 0.15 phosphate 398.5
10mM
23F 0.2 phosphate 336
10mM
23F 0.5 phosphate 179.1
Example 2¨ conjugation of 23F to CRM197 using reductive amination and CDAP
chemistry
27
CA 02791926 2013-10-01
Reductive amination
1g of PS23F was dissolved in 500m1 of 10mM KH2PO4, pH 7.15. This solution was
incubated
at room temperature for two hours. The pH was adjusted to 6.0N with 1M HCI.
111mg of
periodate (Na104, 0.4 molar equivalents of periodate) was added to the PS23F
solution, and
the solution was incubated for 17 hours in the dark at room temperature to
oxidise PS23F.
The solution was then diafiltered against WFI.
The activated PS23F was lyophilised with the CRM197 protein (at a CRM/PS ratio
(w/w):
0.625) in the presence of a stabilising agent.
900mg of the lyophilised PS23F/CRM197 mixture was solubilised by addition of
350m1 of
DMSO solvent and incubating for 2 hours at room temperature. To reduce the
PS23F/CRM197 mixture 1molar equivalent of NaBH3CN was added (735plof a
solution of
100mg/m1 in WFI). The solution was incubated for a further 40 hours room
temperature
(15 C-25 C) under agitation. After this time 2 molar equivalent of NaBH4
(100mg/mlin WFI)
was added and the solution incubated for 4 hours at room temperature. 2200m1
of 150mM
NaCI was added before diafiltration (cut-off 100kDa) and purification by DEAE.
The fractions
of interest were pooled and filtered through a 0.22pm filter.
CDAP
200mg of microfluidized PS23F was dissolved in water until a concentration of
10mg/m1 was
obtained. NaCl was added to this solution at a final concentration of 2M.
Sufficient CDAP solution (100mg/mlfreshly prepared in 5/50 v/v
acetonitrile/VVF1) was added
to reach a CDAP:PS ratio of 0.75mg/mg PS.
After 90 seconds, the pH was raised to pH 9.5 by addition of 0.1N NaOH.
3 minutes later sufficient CRM197 (10mg/m1 in 0.15M NaC1) was added to reach a
ratio of
1.5 (CRM197:PS (w/w)), the pH was maintained at pH 9.5. This solution was
incubated for 1
hour at pH 9.5.
After this coupling step, 10m1 of 2M glycine solution was added to the mixture
and the pH
was adjusted to pH9.0 (the quenching pH). The solution was stirred for 30
minutes at room
temperature. The conjugate was purified using a 5pm filter followed by
Sephacryl TM S400HR
28
CA 02791926 2013-10-01
(XK50/100) which removes small molecules and unconjugated polysaccharides and
protein.
The flow rate was fixed at 150m1/hour. Elution was achieved using 150mM NaCI.
The
fractions of interest were pooled and filtered using Milipack 20. The
resulting conjugate had
a final CRM197/PS ratio (w/w) of 1.35/w.
Example 3 ¨ Immunogenicity of 23F-CRM197 conjugates made by reductive
amination
and CDAP chemistry
Conjugates were made using the methods described in example 2. Female guinea
pigs were
immunized intramuscularly three times (at days 0, 14 and 28) with 0.25pg of
the PS23F-
CRM197 conjugates. Animals were bled on day 42 and the antibody response
directed
against PS23F was measured by ELISA and OPA.
ELI SA
Microplates were coated with purified pneumococcal polysaccharide in PBS
buffer. The
plates were washed four times with 0.9% NaCl and 0.05% Tween TM 20. Sera were
incubated
for 1 hour at 37 C with CPS (VN) in PBS 0.05 % Tween 20. Sera were added to
the
microwells and serially diluted (two-fold dilution step) in PBS- 0.05% Tween.
The plates were
incubated under agitation for 30 minutes at room temperature. The plates were
washed as
above and an anti-guinea pig IgG antibodies peroxydase conjugate was added,
the plates
were then incubated for 30 minutes at RT. After washing, the substrate (4 mg
of OPDA in 10
ml of citrate 0.1M pH 4.5 and 5 pl of H202) was added to each well for 15
minutes. The
reaction was stopped by addition of HCI 1N. Absorbance was read at 490-620 nm
using a
spectrophotometer. The colour developed is directly proportional to the amount
of antibody
present in the serum. The level of anti-PS IgG present in the sera is
determined by
comparison to the reference curve serum added on each plate and expressed in
pg/ml.
Results were analysed statistically after assuming homogeneity of variance
(checked by
Cochrans's C test) and normality (checked using the Shapiro-Wilk test). All
statistics were
carried out using Anova TM (Tukey-HSD) on log transformation concentration
IgG.
Opsonophaqocvtosis
Serum samples were heated for 45 min at 56 C to inactivate any remaining
endogenous
complement. Twenty-five microlitre aliquots of each 1:2 diluted serum sample
were serially
diluted (two fold) in 25 pl OPA buffer (HBSS-14.4% inactivated FBS) per well
of a 96-well
29
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
round bottom microtitre plate. Subsequently, 25 pl of a mixture of activated
HL-60 cells (1 x
107 cells/m1), freshly thawed pneumococcal working seed and freshly thawed
baby rabbit
complement in an e.g. 4/2/1 ratio (v/v/v) was added to the diluted sera to
yield a final volume
of 50 pl. The assay plate was incubated for 2 h at 37 C with orbital shaking
(210 rpm) to
promote the phagocytic process. The reaction was stopped by laying the
microplate on ice
for at least 1 min. A 20 pl aliquot of each well of the plate was then
transferred into the
corresponding well of a 96-well flat bottom microplate and 50 pl of
Todd¨Hewitt Broth-0.9%
agar was added to each well. After overnight incubation at 37 C and 5% 002,
pneumococcal colonies appearing in the agar were counted using an automated
image
analysis system (KS 400, Zeiss, Oberkochen, Germany). Eight wells without
serum sample
were used as bacterial controls to determine the number of pneumococci per
well. The mean
number of CFU of the control wells was determined and used for the calculation
of the killing
activity for each serum sample. The OPA titre for the serum samples was
determined by the
reciprocal dilution of serum able to facilitate 50% killing of the
pneumococci. The
opsonophagocytic titre was calculated by using a 4-parameter curve fit
analysis.
Results were analysed statistically after assuming homogeneity of variance
(checked by
Cochrans's C test) and normality (checked using the Shapiro-Wilk test). All
statistics were
performed by Anova (Tukey-HSD) on log transformation concentration IgG for
ELISA and
Kruskal-Wallis on log dilution for OPA.
A significantly higher antibody response was induced in the guinea pigs after
immunisation
with P523F-0RM197 conjugated by reductive amination than P523F-0RM197
conjugated
by CDAP chemistry as seen in figure 2.
Assay 23F-0RM197 made by 23F-0RM197 made by
reductive amination CDAP
ELISA Titer (pg/ml) 213.3 40.5
OPA (50% killing) 9232 591
Table 2
Example 4¨ a further example of reductive amination of 23F
23F-CRM-RA-116
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
150 mg of native PS23F (PS23FP114) was dissolved at a concentration of 2 mg/ml
in 10
mM phosphate buffer (pH 7.2) for 4 hours. After dissolution, pH was adjusted
to pH 6.0 with
1N HCI. Then 0.4 molar equivalent of periodate (Na 104) was added to the PS
solution and
incubated for 17 hrs in the dark at 25 C. The solution is then diafiltered
(cut off 30 kDa)
against WFI and the oxidised PS was filtered on 0.22 pm membrane.
50 mg of oxidised PS and 75 mg of CRM197 were lyophilized together (CRM/PS
ratio (w/w):
1.5/1) in the presence of a stabilising agent. Lyophilized PS + CRM197 was
solubilised with
20 ml of DMSO for 2 hrs at room temperature (15-25 C). 1 molar equivalent of
TAB (Sodium
triacetoxyborohydride) was then added (13.7 mg) and after 17 hrs under
agitation, 2 molar
equivalent of NaBH4(100 mg/ml in 0.1M NaOH) was added followed by an
incubation at
room temperature for 30 minutes. The solution was diluted 5x by addition of
WFI followed by
a diafiltration (cut-off 30 kDa) against 10 mM phosphate buffer, 150 mM NaCI
pH 7.2. The
conjugate was then loaded onto DEAE resin and eluted in 10 mM phosphate
buffer, 500 mM
NaCI pH 7.2. The conjugate was finally filtered on 0.22 pm. The resulting
conjugate has a
final CRM/PS ratio (w/w) of 2.3 /1.
For further conjugates, a second diafiltration step was added after DEAE
column in order to
change the buffer (150 mM NaCI as final buffer).
Example 5¨ conjugation of 6B to CRM197 using reductive amination (with
different
protein:saccharide ratios and different sized microfluidised 6B saccharides)
and
CDAP chemistry
6B-CRM-RA-122
200 mg of microfluidized PS6B (84 kDa, 11.7 mg/ml) was diluted at 2 mg/ml in
10 mM
phosphate buffer (pH 7.2). pH was adjusted to pH 6.0 with 1N HCI. Then 0.1
molar
equivalent of periodate (Na 104) was added to the PS solution and incubated
for 17 hrs in
the dark at room temperature. The solution is then diafiltered (cut off 30
kDa) against WFI.
50 mg of PS and 30 mg of CRM197 were lyophilized together (CRM/PS ratio (w/w):
0.6/1) in
the presence of a stabilising agent. Lyophilized PS + CRM197 were solubilised
with 20 ml of
DMSO for 3 hrs at room temperature. Then 2.5 molar equivalent of TAB (Sodium
triacetoxyborohydride) was added (38.7 mg) and after 16 hrs under agitation, 2
molar
equivalent of NaBH4(100 mg/ml in 0.1M NaOH) was added followed by an
incubation at
room temperature for 30 minutes. The solution was diluted 4x by addition of
WFI followed by
31
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
a diafiltration (cut-off 100 kDa). The conjugate was then filtered on 0.22 pm.
The resulting
conjugate has a final CRM/PS ratio (w/w) of 1.1/1.
6B-CRM-RA-123:
Microfluidized PS6B (84 kDa) was conjugated to CRM197 as described for 6B-CRM-
RA-122
except the freeze-drying step was carried out using an initial CRM197/PS ratio
(w/w) of 2/1
and 30m1 of DMSO was used for the dissolution in DMSO step (instead of 20 ml).
The
resulting conjugate had a final CRM/PS ratio (w/w) of 3.0/1.
6B-CRM-RA-124:
200 mg of microfluidized PS6B (350 kDa, 11.7 mg/ml) having a molecular weight
of 350 kDa
was diluted to 2 mg/ml in 10 mM phosphate buffer (pH 7.2). pH was adjusted to
pH 6.0 with
1N HCI. Then 0.1 molar equivalent of periodate (Na 104) was added to the PS
solution and
incubated for 17 hrs in the dark at room temperature. The solution is then
diafiltered (cut off
100 kDa) against WFI. 50 mg of PS and 60 mg of CRM197 were lyophilized
together
(CRM/PS ratio (w/w): 1.2/1) in the presence of a stabilising agent.
Lyophilized PS + CRM197
were solubilised with 20 ml of DMSO for 5 hrs at room temperature. 2.5 molar
equivalent of
TAB (Sodium triacetoxyborohydride) was then added (38.7 mg) and after 16 hrs
under
agitation, 2 molar equivalent of NaBH4 (100 mg/ml in 0.1M NaOH) were added
followed by
incubation for 30 min at room temperature. The solution was diluted 4x by
addition of WFI
followed by a diafiltration (cut-off 100 kDa). The conjugate was then filtered
on 0.22 pm. The
resulting conjugate has a final CRM/PS ratio (w/w) of 1.6/1.
6B-CRM-RA-125:
Microfluidized PS6B (350 kDa) was conjugated to CRM197 as described for 6B-CRM-
RA-
124 except the freeze-drying step was carried out using an initial CRM197/PS
ratio (w/w) of
2/1 and the dissolution in DMSO was carried out using 33 ml (instead of 20
ml). The
resulting conjugate had a final CRM/PS ratio (w/w) of 2.9/1.
6B-CRM-003:
50 mg of microfluidized PS6B were diluted at 10 mg/ml in water (10 mg/ml).
NaCI in solid
form was added to reach a final concentration of 2M. CDAP solution (100 mg/ml
freshly
prepared in 50/50 v/v acetonitrile/WFI) was added to reach the appropriate
CDAP/PS ratio
(1.5 mg/mg PS). After 1.5 minutes, the pH was raised to the activation pH 9.5
by addition of
32
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
0.1N NaOH and was stabilised at this pH until addition of CRM197. After 3
minutes,
CRM197 (10 mg/ml in 0.15 M NaCI) was added to reach a ratio CRM197 /PS (w/w)
of 2; the
pH was maintained at the coupling pH 9.5. The solution was left for 2 hrs
under pH
regulation.
After the coupling step, 2.5 ml of 2M glycine solution was added to the
mixture. The pH was
adjusted to the quenching pH (pH 9.0). The solution was stirred for 30 min at
room
temperature. Then the conjugate was filtered using a 5 pm filter and injected
on Sephacryl
S400HR (XK26/100) column to remove small molecules (including DMAP) and
unconjugated
PS and protein. Flow rate was fixed at 30 ml/h. Elution was carried out in 150
mM NaCI.
Interesting fractions were pooled and filtered on Millipack 20. The resulting
conjugate had a
final CRM197/PS ratio (w/w) of 1.5/1.
6B-CRM-RA-144
1 g of microfluidized PS6B (245 kDa, 9.47 mg/ml) was diluted to 2 mg/ml in 10
mM
phosphate buffer (pH 7.2). The pH was adjusted to pH 6.0 with 1N HCI. 0.1
molar equivalent
of periodate (Na104) was then added to the PS solution and incubated for 18
hrs in the dark
at room temperature. The solution was then diafiltered against WFI (Sartocon
Slice200
Hydrosart 100kDa). 200 mg of oxidized PS and 240 mg of CRM197 were lyophilized
together (CRM/PS ratio (w/w): 1.2/1) in the presence of a stabilising agent.
Lyophilized PS +
CRM197 were solubilised with 80 ml of DMSO for 6 hrs at 25 C. Then 2.5 molar
equivalent
of TAB (Sodium triacetoxyborohydride) was added (154.9 mg) and after 16 hrs
under
agitation at 25 C, 2 molar equivalent of NaBH4(100 mg/ml in 0.1M NaOH) was
added and
incubated for 30 min. The solution was diluted 5x in WFI and after 30 min was
diafiltered 10x
with 150 mM NaCI and then 5x with PO4 (K/K2) 10mM pH7.2+ 150 mM NaCI
(Sartorius
Sartocon Slice 200 Hydrosart 100 kDa). Then the retentate was loaded onto a
DEAE column
(XK26/40). The column was washed with PO4(K/K2) 10mM pH7.2 /NaCI 150mM buffer.
The
conjugate was eluted with PO4(K/K2) 10mM pH7.2 /NaCI 500 mM buffer. The eluate
was
concentrated and diafiltered with 5 volumes of 150 mM NaCI and then filtered
on 0.22 pm
filter. The resulting conjugate has a final CRM/PS ratio (w/w) of 1.6/1.
Example 6¨ Immunodenicity of 6B-CRM197 conjugates made by reductive amination
and CDAP chemistry
33
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
Groups of 40 female Balb/c mice (4 weeks-old) were immunized intramuscularly
three times
at days 0, 14 and 28 with 0.1 pg of PS6B conjugates produced by reductive
amination or
CDAP chemistry formulated on AlPO4. PS6B-PD was used as benchmark. Mice were
bled
on day 42 and the antibody response directed against each antigen was measured
by ELISA
and OPA.
Groups of 20 female guinea pig (150 gr from Hartley) were immunized
intramuscularly three
times at days 0, 14 and 28 with 0.25 pg of PS6B conjugates produced by
reductive
amination or CDAP chemistry adjuvanted with AlPO4. PS6B-PD was used as
benchmark.
Guinea pigs were bled on day 42 and the antibody response directed against
each antigen
was measured by ELISA and OPA.
Mouse and Guinea pig OPA
Serum samples were heated for 45 min at 56 C to inactivate any remaining
endogenous
complement. Twenty-five microlitre aliquots of each 1:2 diluted serum sample
was two-fold
serially diluted in 25 pl OPA buffer (HBSS-14.4% inactivated FBS) per well of
a 96-well
round bottom microtitre plate. Subsequently, 25 pl of a mixture of activated
HL-60 cells (1 x
107 cells/m1), freshly thawed pneumococcal working seed and freshly thawed
baby rabbit
complement in an e.g. 4/2/1 ratio (v/v/v) were added to the diluted sera to
yield a final
volume of 50 pl. The assay plate was incubated for 2 h at 37 C with orbital
shaking (210
rpm) to promote the phagocytic process. The reaction was stopped by laying the
microplate
on ice for at least 1 min. A 20 pl aliquot of each well of the plate was then
transferred into the
corresponding well of a 96-well flat bottom microplate and 50 pl of
Todd¨Hewitt Broth-0.9%
agar was added to each well. After overnight incubation at 37 C and 5% 002,
pneumococcal colonies appearing in the agar were counted using an automated
image
analysis system (KS 400, Zeiss, Oberkochen, Germany). Eight wells without
serum sample
were used as bacterial controls to determine the number of pneumococci per
well. The mean
number of CFU of the control wells was determined and used for the calculation
of the killing
activity for each serum sample. The OPA titre for the serum samples was
determined by the
reciprocal dilution of serum able to facilitate 50% killing of the
pneumococci. The
opsonophagocytic titre was calculated by using a 4-parameter curve fit
analysis.
Table 3 describes the GMC levels obtained by immunisation of balb/c mice with
the
conjugates made using the methods of example 4.
34
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
G1 G2 G3 G4 G5 G6
PSO6B-CRM122 PSO6B-CRM123 PSO6B-CRM124 PSO6B-CRM125 PSO6B-CRM003
PSO6B-PD
Subject/Result
(R:1/1.PS 84 (R:3/1.PS 84 kDa)
(R:1.5/1.PS 350 kDa) (R:2.9/1.PS 350 kDa) (CDAP)
GMC (UG-ML) 0.83 0.37 1.18 0.64 0.31
0.10
Responders(%) 31/40 26/40 33/40 29/40 29/40
15/40
Table 3
The immunogenicity of these conjugates in balb/c mice is described in figure
3. Together
figure 3, and table 3 demonstrate that in the mouse model the conjugates
produced by
reductive amination were comparable with those produced using CDAP chemistry.
In
particular figure 3 demonstrates that the immunogenicities of the conjugates
produced using
reductive amination was higher than the immunogenicity of the conjugate made
using CDAP
chemistry.
Table 4 describes the GMC levels obtained by immunisation of guinea pigs with
the
conjugates made using the methods of example 4.
G1 G2 G3 G4 G5 G6
PSO6B-CRM 122 PSO6B-CRM 123 PSO6B-CRM124 PSO6B-CRM 125
Subject/Res ult PSO6B-CRM 003 (CDAP)
PSO6B-PD
(R:1/1 ,PS 84 k Da) (R:3/1,PS84 k Da) (R:1.5/1,PS0350 k Da)
(R:2.9/1 ,PS 350 k Da)
GMC (UG-ML) 3.51 7.70 2.84 19.93 3.70
1.55
Res ponders (%) 20/20 20/20 20/20 20/20 20/20
20/20
Table 4
The immunogenicity of these conjugates in guinea pigs is described in figure
4. Similar to
the experiments carried out in the mouse model, the results in table 4 and
figure 4 show that
the conjugates produced by reductive amination were comparable with those
produced
using CDAP chemistry, in particular PSO6B-CRM125 demonstrated significantly
higher GMC
levels and immunogenicities than the conjugate produced using CDAP.
Example 7 Conjugation of Hib to tetanus toxoid using reductive amination
Hib-104-L5080
2.9 g of PS (orcinol dosage, AHIBCPA007 lot) were dissolved in 260 ml of 10 mM
phosphate
buffer (Na/K2) pH 6.2 for 4h30 at room temperature and then overnight at +4 C.
The
viscosity follow-up was done during the dissolution. After 4 hours dissolution
the viscosity
seemed to be stable. PS was diluted at 10 mg/ml with phosphate buffer and then
oxidised in
the dark with 0.07 molar equivalent of Nalat during 60 minutes. Oxidised PS
was diafiltered
(Sartorius Hydrosart 2 kDa) against 3.5 volumes of phosphate buffer and then
filtered on a
0.22pm filter. The number of repeating units obtained after oxidation was
estimated by 1H-
NMR and was found to be around 21.
CA 02791926 2012-09-04
WO 2011/110531
PCT/EP2011/053400
Hib-TT-LS210, 212 and 213
200 mg of oxidised PS (14.56 mg/ml) were mixed with 300 mg of TT (31.18 mg/ml,
TT/PS
ratio (w/w): 1.5/1) and diluted to 4 mg/ml with 36.64 ml of 10 mM phosphate
buffer (Na/K2)
pH 6.2. The solution was lyophilized in the presence of a stabilising agent.
Lyophilized PS +
TT was solubilised with 20 ml of DMSO for 6 hrs at 25 C. Then 10 Meq of TAB
(Sodium
triacetoxyborohydride) were added (38.7 mg) and after 16 hrs under agitation,
2 molar
equivalent of NaBH4 (100 mg/ml in 0.1M NaOH) was added followed by an
incubation for 30
min at room temperature. The solution was diluted 3x by addition of WFI
followed by a
diafiltration step (5 volumes of WFI followed by 5 volumes of 10 mM acetate
buffer 150 mM
NaCI pH 6.2, 100 kDa MWCO). The sample was then loaded on Sephacryl S300HR
resin.
Elution was carried out in 10 mM acetate buffer using 150 mM NaCI (pH 6.2).
Interesting
fractions were pooled and filtered on a 0.22pm filter. The resulting
conjugates had a final
TT/PS ratio (w/w) of 2.1/1.
36
